Cardiovascular risk associated with glucagon-like peptide-1 receptor agonists versus other conventional glucose-lowering drugs in patients with type-2 diabetes: protocol for a nationwide observational comparative study in routine care

Cardiovascular risk associated with glucagon-like peptide-1 receptor agonists versus other conventional glucose-lowering drugs in patients with type-2 diabetes: protocol for a nationwide observational comparative study in routine care

Introduction Several cardiovascular outcome trials have been conducted to assess the cardiovascular safety and efficacy of glucagon-like peptide-1 receptor agonists (GLP1-RAs) on cardiorenal outcomes in patients with type-2 diabetes (T2D). However, the strict requirements of randomised controlled tr...

Full description

Saved in:
Bibliographic Details
Main Authors: François Schiele, Mikael Mazighi, Nicolas Danchin, Igor Sibon, Gilles Lemesle, Kamel Mohammedi, Laurent Fauchier, Bruno Detournay, Alexandre Caron, Corinne Emery, Camille Nevoret, Lucile Vigié, Christine Massien
Format: Article
Language:English
Published: BMJ Publishing Group 2025-01-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/15/1/e087790.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items